Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies

Mysore S. Anil Kumar, Sheng Guang Xiao, Billie Fyfe, Debra Sierka, Michael Heifets, Michael J. Moritz, Muhammad I. Saeed, Aparna Kumar

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: Reducing chronic steroid exposure is important to minimize steroid-related morbidity, particularly for susceptible renal transplant recipients. Steroid-free and steroid-sparing protocols have shown benefits, but safety has not been established for all populations. We investigated the safety of steroid avoidance (SA) in a population including African-Americans, using modern immunosuppression with protocol biopsy monitoring. Methods: A randomized-controlled SA trial (early discontinuation, days 2-7) was conducted in a population (n = 77) including African-Americans and cadaveric kidney recipients. Patients received basiliximab, cyclosporine (CsA), and mycophenolate mofetil (MMF). In controls, steroids were tapered to 5 mg prednisone/d by day 30. Protocol biopsies were performed (1, 6, 12 and 24 months) to evaluate subclinical acute rejection (SCAR) and chronic allograft nephropathy (CAN). Results: The SA did not result in significantly higher incidences of graft loss, AR, SCAR, CAN, or renal fibrosis. SA patients experienced similar renal function, comparable serum lipid levels, and a trend toward fewer cases of new-onset diabetes. Clinical outcomes of African-American and non-African-American patients did not significantly differ. Conclusions: The SA is safe in the context of basiliximab induction and CsA-based immunosuppression. This protocol could minimize steroid-related side effects in susceptible groups, including African-Americans, without increasing the risk of AR or graft failure.

Original languageEnglish (US)
Pages (from-to)61-69
Number of pages9
JournalClinical Transplantation
Volume19
Issue number1
DOIs
StatePublished - Feb 1 2005
Externally publishedYes

Fingerprint

Kidney Transplantation
Immunosuppression
Cyclosporine
Steroids
Biopsy
African Americans
Kidney
Allografts
basiliximab
Population
Mycophenolic Acid
Transplants
Safety
Prednisone
Fibrosis
Morbidity
Lipids
Incidence

Keywords

  • African-American
  • Cadaveric organs
  • Kidney transplantation
  • Post transplantation diabetes
  • Protocol biopsy
  • Simulect

ASJC Scopus subject areas

  • Transplantation

Cite this

Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. / Anil Kumar, Mysore S.; Xiao, Sheng Guang; Fyfe, Billie; Sierka, Debra; Heifets, Michael; Moritz, Michael J.; Saeed, Muhammad I.; Kumar, Aparna.

In: Clinical Transplantation, Vol. 19, No. 1, 01.02.2005, p. 61-69.

Research output: Contribution to journalArticle

Anil Kumar, Mysore S. ; Xiao, Sheng Guang ; Fyfe, Billie ; Sierka, Debra ; Heifets, Michael ; Moritz, Michael J. ; Saeed, Muhammad I. ; Kumar, Aparna. / Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. In: Clinical Transplantation. 2005 ; Vol. 19, No. 1. pp. 61-69.
@article{f6f5db5c7e65480b91e27c52aef9ad85,
title = "Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies",
abstract = "Background: Reducing chronic steroid exposure is important to minimize steroid-related morbidity, particularly for susceptible renal transplant recipients. Steroid-free and steroid-sparing protocols have shown benefits, but safety has not been established for all populations. We investigated the safety of steroid avoidance (SA) in a population including African-Americans, using modern immunosuppression with protocol biopsy monitoring. Methods: A randomized-controlled SA trial (early discontinuation, days 2-7) was conducted in a population (n = 77) including African-Americans and cadaveric kidney recipients. Patients received basiliximab, cyclosporine (CsA), and mycophenolate mofetil (MMF). In controls, steroids were tapered to 5 mg prednisone/d by day 30. Protocol biopsies were performed (1, 6, 12 and 24 months) to evaluate subclinical acute rejection (SCAR) and chronic allograft nephropathy (CAN). Results: The SA did not result in significantly higher incidences of graft loss, AR, SCAR, CAN, or renal fibrosis. SA patients experienced similar renal function, comparable serum lipid levels, and a trend toward fewer cases of new-onset diabetes. Clinical outcomes of African-American and non-African-American patients did not significantly differ. Conclusions: The SA is safe in the context of basiliximab induction and CsA-based immunosuppression. This protocol could minimize steroid-related side effects in susceptible groups, including African-Americans, without increasing the risk of AR or graft failure.",
keywords = "African-American, Cadaveric organs, Kidney transplantation, Post transplantation diabetes, Protocol biopsy, Simulect",
author = "{Anil Kumar}, {Mysore S.} and Xiao, {Sheng Guang} and Billie Fyfe and Debra Sierka and Michael Heifets and Moritz, {Michael J.} and Saeed, {Muhammad I.} and Aparna Kumar",
year = "2005",
month = "2",
day = "1",
doi = "10.1111/j.1399-0012.2004.00298.x",
language = "English (US)",
volume = "19",
pages = "61--69",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies

AU - Anil Kumar, Mysore S.

AU - Xiao, Sheng Guang

AU - Fyfe, Billie

AU - Sierka, Debra

AU - Heifets, Michael

AU - Moritz, Michael J.

AU - Saeed, Muhammad I.

AU - Kumar, Aparna

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Background: Reducing chronic steroid exposure is important to minimize steroid-related morbidity, particularly for susceptible renal transplant recipients. Steroid-free and steroid-sparing protocols have shown benefits, but safety has not been established for all populations. We investigated the safety of steroid avoidance (SA) in a population including African-Americans, using modern immunosuppression with protocol biopsy monitoring. Methods: A randomized-controlled SA trial (early discontinuation, days 2-7) was conducted in a population (n = 77) including African-Americans and cadaveric kidney recipients. Patients received basiliximab, cyclosporine (CsA), and mycophenolate mofetil (MMF). In controls, steroids were tapered to 5 mg prednisone/d by day 30. Protocol biopsies were performed (1, 6, 12 and 24 months) to evaluate subclinical acute rejection (SCAR) and chronic allograft nephropathy (CAN). Results: The SA did not result in significantly higher incidences of graft loss, AR, SCAR, CAN, or renal fibrosis. SA patients experienced similar renal function, comparable serum lipid levels, and a trend toward fewer cases of new-onset diabetes. Clinical outcomes of African-American and non-African-American patients did not significantly differ. Conclusions: The SA is safe in the context of basiliximab induction and CsA-based immunosuppression. This protocol could minimize steroid-related side effects in susceptible groups, including African-Americans, without increasing the risk of AR or graft failure.

AB - Background: Reducing chronic steroid exposure is important to minimize steroid-related morbidity, particularly for susceptible renal transplant recipients. Steroid-free and steroid-sparing protocols have shown benefits, but safety has not been established for all populations. We investigated the safety of steroid avoidance (SA) in a population including African-Americans, using modern immunosuppression with protocol biopsy monitoring. Methods: A randomized-controlled SA trial (early discontinuation, days 2-7) was conducted in a population (n = 77) including African-Americans and cadaveric kidney recipients. Patients received basiliximab, cyclosporine (CsA), and mycophenolate mofetil (MMF). In controls, steroids were tapered to 5 mg prednisone/d by day 30. Protocol biopsies were performed (1, 6, 12 and 24 months) to evaluate subclinical acute rejection (SCAR) and chronic allograft nephropathy (CAN). Results: The SA did not result in significantly higher incidences of graft loss, AR, SCAR, CAN, or renal fibrosis. SA patients experienced similar renal function, comparable serum lipid levels, and a trend toward fewer cases of new-onset diabetes. Clinical outcomes of African-American and non-African-American patients did not significantly differ. Conclusions: The SA is safe in the context of basiliximab induction and CsA-based immunosuppression. This protocol could minimize steroid-related side effects in susceptible groups, including African-Americans, without increasing the risk of AR or graft failure.

KW - African-American

KW - Cadaveric organs

KW - Kidney transplantation

KW - Post transplantation diabetes

KW - Protocol biopsy

KW - Simulect

UR - http://www.scopus.com/inward/record.url?scp=13644263690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13644263690&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2004.00298.x

DO - 10.1111/j.1399-0012.2004.00298.x

M3 - Article

C2 - 15659136

AN - SCOPUS:13644263690

VL - 19

SP - 61

EP - 69

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 1

ER -